Cancer Medicine最新文献

{"title":"Research Advances of the Effects of Food and Medicine Homology Substances on Gastric Cancer","authors":"Zhengyang Hao,&nbsp;Xiangjun Chen,&nbsp;Wenqian Tang,&nbsp;Ruipeng Wu,&nbsp;Bei Xue,&nbsp;Jingzhe Chen,&nbsp;Yidan Zhang,&nbsp;Shaokang Wang","doi":"10.1002/cam4.71242","DOIUrl":"10.1002/cam4.71242","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Gastric cancer (GC), a common malignant tumor, poses a significant threat to human health. Conventional radiotherapy and chemotherapy regimens come with significant drawbacks, including high toxicity, adverse side effects, inadequate targeting ability, and the potential for developing drug resistance, which ultimately diminishes patients' overall well-being.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Food and medicine homology substances exhibit favorable pharmacological activity and minimal toxic side effects. They comprise a range of components that are beneficial to the human body, including high-quality proteins, vitamins, minerals, and other biologically active components such as polysaccharides, flavonoids, saponins, and alkaloids. In recent years, they have attracted considerable attention in the field of GC prevention and treatment. A comprehensive review of extant literature, alongside a rigorous analysis of contemporary nutrition and traditional Chinese medicine, forms the foundation of this study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Its systematic approach encompasses the examination of the effects and mechanisms of food and medicine homology substances and their active ingredients on the prophylaxis and therapy of GC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The study's findings expand the cognitive boundaries of GC prevention and improvement and offer novel insights and directions for the development of clinical anticancer therapeutic drugs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 19","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145184376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SIRT1 Expression in Human Gastrointestinal Tumors and Its Clinical Significance","authors":"Wenxuan Liu,&nbsp;Xinyi Li,&nbsp;Wenhong Deng","doi":"10.1002/cam4.71217","DOIUrl":"10.1002/cam4.71217","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study aimed to investigate the expression levels of SIRT1 protein in gastric (GC), colon (CC), and rectal cancer (RC) tissues and patient plasma, analyze its correlation with clinicopathological features and prognosis, and preliminarily explore its relationship with the tumor immune microenvironment.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Plasma samples were collected from 198 gastrointestinal cancer patients (66 each of GC, CC, and RC) and 66 healthy volunteers. Additionally, cancerous and adjacent normal tissues were obtained from 45 of these patients (15 pairs for each cancer type). SIRT1 concentration in plasma was detected using Enzyme-Linked Immunosorbent Assay (ELISA). SIRT1 protein expression in tissues was examined using Immunohistochemistry (IHC) and Western Blotting. Bioinformatic analysis was performed using TCGA and GEPIA databases. The correlation between SIRT1 and immune cell infiltration was analyzed via the TIMER database. Statistical analyses were conducted using SPSS software.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Plasma SIRT1 concentration was significantly higher in the GC group compared to healthy controls (&lt;i&gt;p&lt;/i&gt; = 0.045), while it was significantly lower in the CC and RC groups (&lt;i&gt;p&lt;/i&gt; = 0.007 and &lt;i&gt;p&lt;/i&gt; = 0.009, respectively). In tissues, SIRT1 expression was up-regulated in GC but down-regulated in colorectal cancer (CC and RC) tissues (&lt;i&gt;p&lt;/i&gt; &lt; 0.05). SIRT1 expression levels were significantly correlated with clinicopathological features including tumor differentiation degree, depth of invasion, TNM stage, distant metastasis (in colorectal cancer), and lymph node metastasis (in RC) (&lt;i&gt;p&lt;/i&gt; &lt; 0.05). Survival analysis revealed that high SIRT1 expression was associated with poorer overall survival (OS) in GC patients (&lt;i&gt;p&lt;/i&gt; = 0.032), while low expression was associated with poorer OS in RC patients (&lt;i&gt;p&lt;/i&gt; = 0.027). Plasma SIRT1 levels showed significant correlations with various tumor markers (e.g., CEA, CA199, CA125, CA724). Furthermore, SIRT1 expression was positively correlated with the infiltration levels of immune cells such as CD4+ T cells, CD8+ T cells, macrophages, and neutrophils.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;SIRT1 expression in gastrointestinal tumors is tissue-specific (upregulated in GC, downregulated in colorectal cancer). Its expression level is closely associated with malignant progression and patient prognosis, and it may be involved in the modulation of the tumor immune microenvironment. SIRT1 shows promise a","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 19","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145184416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Association of Primary Lung Cancer With Urological Cancers: A Bidirectional Mendelian Randomization Study and SEER Database Validation","authors":"Hao Zhou,&nbsp;Zihao Feng,&nbsp;Cunjing Zheng,&nbsp;Ling Xia,&nbsp;Ziran Dai,&nbsp;Zheyu Ai,&nbsp;Zhenwei Li,&nbsp;Kezhi Liu,&nbsp;Yinghan Wang,&nbsp;Ning Su,&nbsp;Zhenhua Chen,&nbsp;Jing Zhang,&nbsp;Xiaohan Jin","doi":"10.1002/cam4.71272","DOIUrl":"10.1002/cam4.71272","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Previous studies reported an association between lung cancer (LC) and partial urological cancers (UCs). However, the exact causal association between LC and UCs remains obscure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A two-sample bidirectional Mendelian randomization (MR) and the Genetic Risk Scores (GRS) method were used to assess the genetic relationships between LC and UCs. The risk of second primary cancer (SPC) was validated using the Surveillance, Epidemiology, and End Results (SEER) database.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>MR analysis demonstrated genetic associations between overall LC and lung adenocarcinoma (LUAD) with renal cell carcinoma (RCC) (overall LC: OR [95% CI] = 1.214 [1.003–1.469], <i>p</i> = 0.046; LUAD: OR [95% CI] = 1.144 [1.029–1.271], <i>p</i> = 0.012). The GRS method also yielded consistent results (overall LC: OR [95% CI] = 1.229 [1.067–1.414], <i>p</i> = 0.004; LUAD: OR [95% CI] = 1.125 [1.019–1.243], <i>p</i> = 0.020). Therefore, this study primarily focused on the significant associations between overall LC and LUAD with RCC. Meanwhile, the SEER database was exploited to confirm the correlation between primary LUAD (PLUAD) and secondary primary RCC (SPC-RCC). The results indicated that the risk of SPC-RCC after PLUAD was substantially higher than the US reference population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The MR study identified genetic associations between LC and UCs, revealing an elevated risk of SPC-RCC after primary LC (PLC), particularly LUAD. This study lays a foundation for SPC-RCC prevention after PLC, indicating the necessity of enhanced surveillance of PLC patients in clinical practice and further research into the shared biological pathways to provide innovative therapeutic alternatives.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 19","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145184413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer: A Real-World Cohort Study in Finland","authors":"Kirsi Hormalainen,&nbsp;Kaisa Marttila,&nbsp;Matti Nykter,&nbsp;Toomas Uibu,&nbsp;Jarkko Ahvonen,&nbsp;Vidal Fey,&nbsp;Mauri Keinänen,&nbsp;Maarit Bärlund,&nbsp;Arja Jukkola","doi":"10.1002/cam4.71250","DOIUrl":"10.1002/cam4.71250","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Non-small cell lung cancer (NSCLC) is a disease with a low survival rate and poor prognosis. Targeted therapies have improved treatment outcomes as driver mutations have been identified, especially in adenocarcinomas. Comprehensive genomic profiling (CGP) provides insights into the genetic mutation profile of cancer and helps identify actionable mutations. The mutational landscape of cancer varies based on the patient's ethnic background, and there is limited information on the genetic profile of NSCLC within the Finnish population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Material and Methods</h3>\u0000 \u0000 <p>We analysed the genetic mutational profile of 96 advanced NSCLCs that underwent CGP between November 2021 and March 2023 at Tampere University Hospital. Additionally, we compared the genomic alterations in our cohort with those in the international datasets.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Clinically actionable alterations associated with a targeted therapy were identified in 45% of patients, including 63% of never-smokers and 41% of ever-smokers. The most common actionable alteration was KRAS G12C (18%), followed by EGFR alterations (14%). However, only 33% of the patients with an actionable alteration received targeted therapy. The median tumour mutational burden (TMB) was 5, with 31% of patients exhibiting a TMB greater than 10.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>CGP affects the treatment strategies for NSCLC. Nearly half of our entire cohort had a genetic alteration eligible for approved targeted therapies. Besides these findings, CGP provides additional data to assess treatment decisions and outcomes, including co-occurring genetic alterations and TMB. In real-world clinical practice, the practical application of this information can be restricted by the varying unavailability of optimal treatments.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 19","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145184357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Follow-Up After Receiving Abnormal Results From Self-Sampled Colorectal and Cervical Cancer Screening Tests Among Underserved Patients","authors":"Jennifer L. Moss,&nbsp;Veronica E. Bernacchi,&nbsp;Juliette Entenman,&nbsp;Heather Costigan,&nbsp;Heather L. Stuckey,&nbsp;Mack T. Ruffin","doi":"10.1002/cam4.71283","DOIUrl":"https://doi.org/10.1002/cam4.71283","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Increasing cancer screening through at-home self-sampling test modalities is a public health priority. Patients with abnormal screening results should receive diagnostic follow-up care; optimizing this process is a challenge. We conducted a mixed methods study to examine the cancer screening process among underserved patients who received abnormal results on a self-sampled cancer screening test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Participants were drawn from a parent study examining the impact of self-sampled colorectal and cervical cancer screening tests among patients at federally qualified health centers in Pennsylvania. Those who had received abnormal results on their screening were completed a survey and semi-structured interview about their experience (<i>n</i> = 5). We conducted mixed methods analysis to examine participants' (1) understanding and follow-up care for abnormal results and (2) satisfaction with the self-sampling cancer screening process.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Quantitatively, participants indicated very high satisfaction with each self-sampled cancer screening, and 60% preferred a self-sampled test for their next cancer screening. Qualitatively, participants differed in the extent to which they seemed to understand their screening results, but they were generally satisfied with the self-sampling process. In mixed methods analysis, participants' baseline knowledge about cancer screening supported better understanding of abnormal screening results, and participants' preference for their next cancer screening was related to their experiences with self-sampling.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Among this sample of patients who received abnormal results on their self-sampled colorectal or cervical cancer screening test, knowledge and understanding were not prerequisites for accessing follow-up care. Satisfaction with the self-sampling screening process was very high. These findings provide additional support for public health priorities to expand access to self-sampling cancer screening tests.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 19","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71283","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145146857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Influence of Sex and Gender on Cancer: A Comprehensive Analysis","authors":"Teresa Gisinger,&nbsp;Alexandra Kautzky-Willer,&nbsp;Alexander Kautzky","doi":"10.1002/cam4.71263","DOIUrl":"https://doi.org/10.1002/cam4.71263","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>Our aim was to untangle the effect of biological sex and psychosocial gender on rates of self-reported cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>For this study, the Austrian Health Information Survey 2019 was used. Individuals with cancer (<i>n</i> = 415) were selected and divided by sex (female 53.3%). Descriptive results were reported as mean/standard deviation or frequency/percentage. Next, the cancer versus non-cancer and female versus male cancer cohorts were compared by using a chi-square test or an unpaired <i>t</i>-test. By logistic regression models adjusted by age, the association of cancer, biological sex, and gender-related variables (including employment status, educational level, marital status, household income and size) was investigated in the total cohort, as well as stratified by sex.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Self-reported cancer was positively related with being unemployed/retired versus employed (OR 2.06, <i>p</i> &lt; 0.001), being married versus single (OR 1.90, <i>p</i> = 0.005), household size over 1 compared to 1 (OR 1.42, <i>p</i> = 0.025), self-reported depression (OR 2.13, <i>p</i> &lt; 0.001), and former smoking (OR 1.84, <i>p</i> &lt; 0.001). A negative relation between having cancer and being a daily smoker was seen (OR 0.22, <i>p</i> = 0.006). No association between cancer and biological sex was found. Similar correlations of gender-related variables on cancer rates were found in the sex-disaggregated analyses; however, marital status as well as daily smoking were not associated with cancer diagnosis in males. In contrast to males, in females former smoking and alcohol consumption showed no association with cancer rates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings suggest that gender-related variables, rather than biological sex, are associated with sel-reported cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 19","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71263","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145146856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Metabolic Syndrome and Its Components and the Risk of Head and Neck Cancer: A Systematic Review and Meta-Analysis","authors":"Qingling Wang,&nbsp;Shiduo Guo,&nbsp;Ruizhe Huang,&nbsp;Zhenju Xu,&nbsp;Dapeng Liang,&nbsp;Yichuan Huang,&nbsp;Yubo Sun,&nbsp;Weiqi Yang,&nbsp;Liwei Jiang","doi":"10.1002/cam4.71262","DOIUrl":"https://doi.org/10.1002/cam4.71262","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The relationship between metabolic syndrome (MetS) and head and neck cancer (HNC) remains controversial. The present meta-analysis evaluated the association between MetS and the risk of developing HNC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A literature search was conducted across various databases, including Embase, Cochrane, PubMed, and Web of Science, to identify studies investigating the relationship between MetS and the risk of HNC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twelve studies involving 55,692 participants were included. We found limited evidence of an association between MetS and the risk of developing HNC (RR = 1.1, 95% CI: 1.0–1.2, <i>p</i> = 0.07, I² = 94%). Similar results were observed for HNC subtypes. Components of MetS revealed that underweight (BMI &lt; 18.5 kg/m²) was associated with an increased risk of HNC (RR = 1.7, 95% CI: 1.5–1.9, <i>p</i> &lt; 0.001). Low high-density lipoprotein (HDL) cholesterol levels (RR = 1.0, 95% CI: 1.0–1.1, <i>p</i> = 0.003), hypertension (RR = 1.1, 95% CI: 1.0–1.1, <i>p</i> = 0.007), and diabetes (RR = 1.1, 95% CI: 1.0–1.2, <i>p</i> = 0.001) were associated with a minimal increase in the risk of HNC. However, high low-density lipoproteins (LDL) cholesterol levels (RR = 0.8, 95% CI: 0.7–0.9, <i>p</i> &lt; 0.001) and high total cholesterol levels (RR = 0.9, 95% CI: 0.9–0.9; <i>p</i> &lt; 0.001) were associated with a reduced risk of HNC. Additionally, an increasing number of MetS components was associated with a higher risk of HNC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In conclusion, our meta-analysis found little evidence of an association between MetS and the risk of developing HNC. However, high LDL and total cholesterol levels may be associated with a reduced risk of HNC, while being underweight may be associated with increased risk of HNC. These results need to be interpreted with caution due to the limited number of supporting studies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 19","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71262","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145135724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reducing Home Labs for Pediatric Patients With Solid Tumors: Impact of a Novel Clinical Practice Guideline on Safety, Cost, and Quality of Life","authors":"Catherine B. Wall,&nbsp;Jill A. MacDonald,&nbsp;Riley Garland,&nbsp;Allison F. O'Neill","doi":"10.1002/cam4.71269","DOIUrl":"https://doi.org/10.1002/cam4.71269","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>For pediatric patients with solid tumors, the use of growth factors following chemotherapy evolved from daily filgrastim to pegylated filgrastim. Currently, post-chemotherapy laboratory work is obtained to monitor for transfusion needs rather than count recovery. We implemented a clinical practice improvement project aimed at identifying the minimum number of labs required to assess transfusion needs, based upon disease and chemotherapeutic regimen, to design guidelines to safely reduce the number of home labs for targeted solid tumor diagnoses by 50% over 2 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively sourced data for a cohort of solid tumor diagnoses and chemotherapeutic regimens to determine the reasons why laboratory work was obtained. We subsequently developed new lab monitoring guidelines and conducted serial teaching sessions and prospective data monitoring post-implementation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Post-implementation data analysis resulted in a reduction in home laboratory draws by 71%, exceeding our a priori set 50% goal. There were no adverse events. Estimated cost savings over 2 years, accounting for provider follow-up, price per lab, and visiting nurse sessions, were $69,898. This reduction in home laboratory draws was interpreted, by decision tree analysis, to reduce the risk and costs associated with central line infections and improve quality of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings indicate that there is a cohort of solid tumor diagnoses that do not require twice weekly bloodwork to monitor for transfusion needs. Implementation of a novel clinical practice guideline resulted in a safe reduction in labs leading to optimized resource utilization, decreased costs, and perceived improvement in quality of life.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 19","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71269","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145135725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Comprehensive Analysis of Diagnosis and Treatment in 99 Cases of Abdominal Schwannoma","authors":"","doi":"10.1002/cam4.71277","DOIUrl":"https://doi.org/10.1002/cam4.71277","url":null,"abstract":"<p>Fan S, Wang H, Sun X, et al. Comprehensive analysis of diagnosis and treatment in 99 cases of abdominal Schwannoma. <i>Cancer Med</i>. 2024; 13:e70140. doi:10.1002/cam4.70140</p><p>In the originally published version of this article, the article type was incorrectly listed as Review. The correct article type is Research Article.</p><p>We apologize for this error.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 19","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71277","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145135729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roles of miR-181 Family Members in OSCC: Implications for Therapy and Diagnostics","authors":"Alexandra Iulia Aghiorghiesei,&nbsp;Andreea Nutu,&nbsp;Nikolay Mehterov,&nbsp;Christos K. Kontos,&nbsp;Boyan Vladimirov,&nbsp;Rares Buduru,&nbsp;Cornelia Braicu,&nbsp;Ioana Berindan-Neagoe","doi":"10.1002/cam4.71266","DOIUrl":"https://doi.org/10.1002/cam4.71266","url":null,"abstract":"<p>Oral squamous cell carcinoma (OSCC) is a common and aggressive form of head and neck cancer, frequently associated with smoking, alcohol consumption, and HPV infection. MicroRNAs (miRNAs) are small, non-coding RNA transcripts that play significant roles in cancer initiation and progression. In this study, we focused on the miR-181 family members' influence on OSCC tumorigenesis and progression, focusing on their distinct biological functions and regulatory mechanisms in OSCC-specific contexts. Attention was given to the potential of these transcripts as biomarkers, considering their differential expression in OSCC tissues and biofluids such as plasma, serum, and saliva. Alterations in salivary miR-181 levels have been correlated with different stages of oral lesion progression, underscoring their utility as non-invasive biomarkers for early detection and risk stratification. Moreover, we discuss the implications of miR-181 family modulation on biological processes in preclinical OSCC studies, highlighting their involvement in cancer hallmarks, including invasion, migration, metastasis, radio- and chemotherapy resistance. These findings underscore the therapeutic and diagnostic potential of the miR-181 family in OSCC management.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 19","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71266","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145135722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}